Literature DB >> 20817668

Risk factors for the development of albuminuria and renal impairment in type 2 diabetes--the Swedish National Diabetes Register (NDR).

Henri Afghahi1, Jan Cederholm, Björn Eliasson, Björn Zethelius, Soffia Gudbjörnsdottir, Henrik Hadimeri, Maria K Svensson.   

Abstract

BACKGROUND: The aim of this study was to identify clinical risk factors associated with the development of albuminuria and renal impairment in patients with type 2 diabetes (T2D). In addition, we evaluated if different equations to estimate renal function had an impact on interpretation of data. This was done in a nationwide population-based study using data from the Swedish National Diabetes Register.
METHODS: Three thousand and six hundred sixty-seven patients with T2D aged 30-74 years with no signs of renal dysfunction at baseline (no albuminuria and eGFR >60 mL/min/1.73 m(2) according to MDRD) were followed up for 5 years (2002-2007). Renal outcomes, development of albuminuria and/or renal impairment [eGFR < 60 mL/min/1.73 m(2) by MDRD or eCrCl > 60 mL/min by Cockgroft-Gault (C-G)] were assessed at follow-up. Univariate regression analyses and stepwise regression models were used to identify significant clinical risk factors for renal outcomes.
RESULTS: Twenty percent of patients developed albuminuria, and 11% renal impairment; thus, ~6-7% of all patients developed non-albuminuric renal impairment. Development of albuminuria or renal impairment was independently associated with high age (all P < 0.001), high systolic BP (all P < 0.02) and elevated triglycerides (all P < 0.02). Additional independent risk factors for albuminuria were high BMI (P < 0.01), high HbA1c (P < 0.001), smoking (P < 0.001), HDL (P < 0.05) and male sex (P < 0.001), and for renal impairment elevated plasma creatinine at baseline and female sex (both P < 0.001). High BMI was an independent risk factor for renal impairment when defined by MDRD (P < 0.01), but low BMI was when defined by C-G (P <  0.001). Adverse effects of BMI on HbA1c, blood pressure and lipids accounted for ~50% of the increase risk for albuminuria, and for 41% of the increased risk for renal impairment (MDRD).
CONCLUSIONS: Distinct sets of risk factors were associated with the development of albuminuria and renal impairment consistent with the concept that they are not entirely linked in patients with type 2 diabetes. Obesity and serum triglycerides are semi-novel risk factors for development of renal dysfunction and BMI accounted for a substantial proportion of the increased risk. The equations used to estimate renal function (MDRD vs. C-G) had an impact on interpretation of data, especially with regard to body composition and gender.

Entities:  

Mesh:

Year:  2010        PMID: 20817668     DOI: 10.1093/ndt/gfq535

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  41 in total

1.  Visit-to-visit blood pressure variability is related to albuminuria variability and progression in patients with type 2 diabetes.

Authors:  S Noshad; M Mousavizadeh; M Mozafari; M Nakhjavani; A Esteghamati
Journal:  J Hum Hypertens       Date:  2013-07-11       Impact factor: 3.012

2.  Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study.

Authors:  Louisa Sukkar; Amy Kang; Carinna Hockham; Tamara Young; Min Jun; Celine Foote; Roberto Pecoits-Filho; Brendon Neuen; Kris Rogers; Carol Pollock; Alan Cass; David Sullivan; Germaine Wong; John Knight; David Peiris; Martin Gallagher; Meg Jardine
Journal:  Diabetes Care       Date:  2020-03-11       Impact factor: 19.112

3.  The combined use of edaravone, diuretics, and nonsteroidal anti-inflammatory drugs caused acute kidney injury in an elderly patient with chronic kidney disease.

Authors:  Guang Jian Liu; Yun Fu Wang; Yan Jun Zeng; Li Ding; Guo Jun Luo; Li Ping Zhang; Jian'e Zhang
Journal:  CEN Case Rep       Date:  2012-06-08

4.  Gender difference in albuminuria and ischemic heart disease in type 2 diabetes.

Authors:  Manouchehr Nakhjavani; Afsaneh Morteza; Yaser Jenab; Azam Ghaneei; Alireza Esteghamati; Maryam Karimi; Alireza Farokhian
Journal:  Clin Med Res       Date:  2011-10-26

5.  Weight loss independently predicts urinary albumin excretion normalization in morbidly obese type 2 diabetic patients undergoing bariatric surgery.

Authors:  Antonio Amor; Amanda Jiménez; Violeta Moizé; Ainitze Ibarzabal; Lílliam Flores; Antonio M Lacy; Josep Vidal
Journal:  Surg Endosc       Date:  2013-01-05       Impact factor: 4.584

6.  Comparison of the Rate of Renal Function Decline in NonProteinuric Patients With and Without Diabetes.

Authors:  Liliane Hobeika; Kelly J Hunt; Benjamin A Neely; John M Arthur
Journal:  Am J Med Sci       Date:  2015-12       Impact factor: 2.378

7.  Estimated glomerular filtration rate and albuminuria: true predictors of cardiovascular events in obese patients with type 2 diabetes?

Authors:  Michael Resl; Greisa Vila; Roland Kraxner; Richard Pacher; Anton Luger; Martin Hülsmann; Stephanie Neuhold; Helmut Brath; Rudolf Prager; Martin Clodi
Journal:  Wien Klin Wochenschr       Date:  2013-09-06       Impact factor: 1.704

8.  The synergistic relationship between estimated GFR and microalbuminuria in predicting long-term progression to ESRD or death in patients with diabetes: results from the Kidney Early Evaluation Program (KEEP).

Authors:  Amit P Amin; Adam T Whaley-Connell; Suying Li; Shu-Cheng Chen; Peter A McCullough; Mikhail N Kosiborod
Journal:  Am J Kidney Dis       Date:  2013-04       Impact factor: 8.860

Review 9.  Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency.

Authors:  Miho Shimizu; Kengo Furuichi; Hitoshi Yokoyama; Tadashi Toyama; Yasunori Iwata; Norihiko Sakai; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2013-10-01       Impact factor: 2.801

Review 10.  Clinical relevance of visit-to-visit blood pressure variability: impact on renal outcomes.

Authors:  G Parati; X Liu; J E Ochoa
Journal:  J Hum Hypertens       Date:  2013-10-17       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.